For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)
To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent chronic lymphocytic leukemia from returning.
DiagnosisChronic Lymphocytic Leukemia
Central FISH blood submission.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1: Ibrutinib plus Obinutuzumab
- Group 2: Ibrutinib plus Obinutuzumab plus Venetoclax (study drug)
For more information, visit ClinicalTrials.gov